Deals & Corporate Governance

  • October 09, 2025

    Biotronik Wants Full 9th Circ. Review Of Whistleblower Ruling

    Biotronik Inc. urged the full Ninth Circuit to review a panel ruling that revived a whistleblower suit alleging the company used unlawful compensation tactics to boost heart-device sales, saying it should have been tossed based on prior disclosures in news articles.

  • October 09, 2025

    Tivity Health Investors Seek Final OK Of $17M Settlement

    An investor in fitness program administrator Tivity Health Inc. has asked a Nashville federal judge for a final nod for an over $17 million deal ending claims the company misled investors about its financial prospects after its $1.3 billion acquisition of troubled weight-loss meal delivery company Nutrisystem.

  • October 08, 2025

    Del. Judge May Have Mallinckrodt Choose: Injunction Or $10M

    A Delaware federal judge said he might ask Mallinckrodt Pharmaceuticals to choose between getting a competitor's inhaled nitric oxide treatment enjoined, or receiving the entire $9.5 million a jury determined it's owed for infringement.

  • October 07, 2025

    Aetna COVID-19 Test Provider Sues Insurer For 'Unpaid' $53M

    A Nebraska company that provided COVID-19 testing for Aetna has filed suit in California federal court, alleging that the insurer owes it more than $53 million for testing services but has refused to pay up.

  • October 07, 2025

    Alto Neuroscience Execs Sued Over Rosy Drug Claims

    An Alto Neuroscience investor claims CEO Amit Etkin and other directors overstated the efficacy of the psychiatric biotech company's lead drug candidate for treating major depressive disorder, according to a lawsuit filed Tuesday in California federal court that alleges the company's stock price plummeted when the truth came out.

  • October 07, 2025

    Bausch And Teva Blocked Cheaper IBS Drug, Retailers Say

    A slew of retailers on Tuesday accused Bausch Health Cos. Inc. and Teva Pharmaceuticals of working together to keep the generic version of an irritable bowel syndrome drug off the market until 2028, forcing the retailers and other purchasers of the drug to pay monopoly prices.

  • October 07, 2025

    Prospect Medical Fights $1M Software Fee Claims In Ch. 11

    Prospect Medical Holdings Inc. says the pending Chapter 11 proceedings for its hospitals in California and Connecticut should keep two technology companies from demanding more than $1 million in payment for disputed software and IT contracts, according to Prospect's filings with a Texas bankruptcy court on Monday.

  • October 07, 2025

    Biogen Says Investors Can't Expand Alzheimer's Drug Suit

    Biogen Inc. said a class of investors suing over alleged misleading statements in connection with the rollout of the company's Alzheimer's drug should not be allowed to needlessly delay resolution by filing an amended complaint expanding the class period and adding new legal theories and claims.

  • October 07, 2025

    Premera Defends IBS Drug Antitrust Claims Against Takeda

    Health insurers and self-insured employers represented by Premera Blue Cross urged a Massachusetts federal judge not to nix a series of state law antitrust claims from the broader certified class action accusing Takeda Pharmaceutical of paying Par Pharmaceuticals to delay generic competition to anticonstipation drug Amitiza.

  • October 07, 2025

    3 Firms Advise On Qualtrics' $6.75B Press Ganey Forsta Buy

    Goodwin Procter LLP and Simpson Thacher & Bartlett LLP are advising Qualtrics on its agreement to acquire Latham & Watkins LLP-led experience analytics firm Press Ganey Forsta for $6.75 billion, in a deal the companies said will create the "most complete platform designed for experience management."

  • October 06, 2025

    2 Firms To Lead Humana Investor Suit Over Post-COVID Costs

    Glancy Prongay & Murray LLP and The Rosen Law Firm will co-lead consolidated shareholder derivative claims against healthcare giant Humana Inc. alleging its brass made the company downplay the "pent-up demand" that pushed up patient utilization rates on the heels of the COVID-19 pandemic.

  • October 06, 2025

    Law Profs Say CareDx False Ad Verdict Should Stand

    Two law professors have urged the Third Circuit to grant medical testing company CareDx's request for another chance to argue why its $45 million false advertising verdict against a rival should be reinstated, saying a ruling nixing the verdict will disallow juries from using circumstantial evidence and encourage false advertisers to "try their luck."

  • October 06, 2025

    Judge Grants Modivcare Permission To Take Ch. 11 Plan Vote

    A Texas bankruptcy judge on Monday permitted Modivcare to send its Chapter 11 plan out for a vote, saying he was going to trust the debtor to move expeditiously towards a confirmation hearing but would divert from the schedule if necessary.

  • October 06, 2025

    High Court Turns Down 6 Patent Cases At Start Of Term

    The U.S. Supreme Court on Monday rejected six petitions in patent-related cases, taking some of its first actions on intellectual property matters this term.

  • October 03, 2025

    Modivcare Can Tap Full $100M Ch. 11 Loan

    A Texas bankruptcy judge Friday agreed to give final approval to medical transport company Modivcare's request to borrow $100 million in debtor-in-possession funds, finding that what the unsecured creditors' committee argued were flaws in the financing arrangement were not actually deal-breakers.

  • October 02, 2025

    NC Court Rejects McGuireWoods' Immunity In Defamation Suit

    A North Carolina appellate court dismissed an interlocutory appeal by McGuireWoods and a former partner in a defamation case over statements about an investigation into the onetime CEO of a managed care organization during a press conference, reiterating its opinion that the statements were "too far afield" to be considered part of a judicial proceeding.

  • October 02, 2025

    NC Chief Judge Scolds Medical Supply Co.'s 'Rude' Demand

    A North Carolina federal judge on Wednesday threw out a medical supply company's suit over COVID-19 test kit profits based on the Chinese citizenship of one party, adding that the plaintiff's impatience with the court amid a judge shortage was "rude."

  • October 02, 2025

    Fed. Circ. Affirms Cutting $10M Med Device IP Verdict To $1

    The Federal Circuit on Thursday said a lower court had properly reduced to $1 what had been a $10 million patent infringement verdict against Intuitive Surgical Inc., saying any amount between the two figures "would require improper guesswork," given the lack of evidence on damages.

  • October 02, 2025

    Many Cos. Not Ready For National Security Risks, Report Says

    At least a third of U.S. companies aren't fully prepared to address key national security compliance risks they face, and the C-suite often isn't aligned with its in-house counsel as to who is primarily responsible for those efforts, according to a new survey from Eversheds Sutherland.

  • October 01, 2025

    Hospitals Turn To Real Estate To Shore Up Finances

    Hospital systems are increasingly turning to their real estate to raise money after years of rising inflation and lagging reimbursement rates, although state regulators have placed more scrutiny on such transactions.

  • October 01, 2025

    Cozen O'Connor Adds Healthcare Litigator To Philly Office

    An attorney with more than three decades of experience representing healthcare providers in litigation matters has recently moved his practice to Cozen O'Connor's Philadelphia shop.

  • September 30, 2025

    McKinsey Trims Endo Suit But Can't Nix Indemnification Claim

    A New York bankruptcy judge trimmed an adversary suit Monday claiming McKinsey & Co. Inc. should pay at least $1.5 billion to cover costs bankrupt pharmaceutical developer Endo International racked up defending against opioid claims, tossing nearly all allegations with leave to amend, but greenlighting an indemnification claim.

  • September 30, 2025

    3rd Circ. Parses 'Could' And 'Would' In Lipitor Lawsuit

    A Third Circuit panel questioned Tuesday whether drug wholesalers and health plans had offered enough evidence that Pfizer Inc. and Ranbaxy Laboratories Ltd. conspired to delay generic competition for the cholesterol drug Lipitor, focusing on whether the U.S. Food and Drug Administration would have approved the competitor earlier than November 2011.

  • September 30, 2025

    Healthcare Deals This Week: Pfizer, Genmab, And More

    There was at least one blockbuster M&A deal and a slew of private fundraises in the healthcare space this past week, marking a potential — albeit faint — bright spot in healthcare dealmaking, despite a difficult past few months for the industry.

  • September 30, 2025

    'Most Favored Nation' Price Deadline Has Passed. Now What?

    A hotly anticipated deadline set by President Donald Trump as part of the administration's efforts to pressure pharmaceutical companies to cut drug prices came and went, leaving the industry to wonder: What's next?

Expert Analysis

  • A Guide For Landlords Pivoting To Medical Office Buildings

    Author Photo

    The current commercial real estate landscape presents a unique opportunity for landlords, real estate developers and investors to accommodate the growing health care industry's need for office buildings, though proper navigation of complex regulations and leasing concerns is necessary, says Mehdi Sinaki at Michelman & Robinson.

  • Unpacking OMB's Proposed Uniform Guidance Rewrite

    Author Photo

    Affected organizations, including state and local governments, should carefully review the Office of Management and Budget's proposed overhaul of uniform rules for administering over $1 trillion in federal funding distributed each year, and take the opportunity to submit comments before the December deadline, says Dismas Locaria at Venable.

  • Judicial Independence Needs Defense Amid Political Threats

    Author Photo

    Amid recent and historic challenges to the judiciary from political forces, safeguarding judicial independence and maintaining the integrity of the legal system is increasingly urgent, says Robert Peck at the Center for Constitutional Litigation.

  • FDI Considerations For UK Venture Capital Transactions

    Author Photo

    With the U.K. National Security and Investment Act highlighting foreign direct investment matters for venture capital transactions, investors dealing with companies connected to the U.K. should be alive to how the act's requirements can affect deal timelines, structures and terms, say lawyers at Covington.

  • How Law Firms Can Use Account-Based Marketing Strategies

    Author Photo

    Amid several evolving legal industry trends, account-based marketing can help law firms uncover additional revenue-generating opportunities with existing clients, with key considerations ranging from data analytics to relationship building, say Jennifer Ramsey at stage LLC and consultant Gina Sponzilli.

  • A Reminder For Drug Cos. To Confirm Orange Book Listings

    Author Photo

    A recent policy statement from the Federal Trade Commission highlights the legal danger that pharmaceutical companies can face for improperly listing patents in the U.S. Food and Drug Administration's Orange Book, which is also an issue in the context of Hatch-Waxman litigation, say attorneys at Kirkland.

  • Strategic Succession Planning At Law Firms Is Crucial

    Author Photo

    Senior partners' reluctance to retire, the rise of the nonequity partner tier and generational differences in expectations are all contributing to an increasing number of departures from BigLaw, making it imperative for firms to encourage retirement among senior ranks and provide clearer leadership pathways to junior attorneys, says Laura Leopard at Leopard Solutions.

  • FTC's Health Co. Suit Indicates Agency's Private Equity Focus

    Author Photo

    The Federal Trade Commission's latest lawsuit against an anesthesia company and its private equity investor highlights the agency's willingness to regulate the health care industry even when relevant acquisitions are relatively dated or when the controlling entity's economic interest is under 50%, say attorneys at Simpson Thacher.

  • Top 4 Antitrust Enforcement Issues In Health Care Today

    Author Photo

    The Federal Trade Commission's recent lawsuit against U.S. Anesthesia Partners exemplifies antitrust enforcement authorities' efforts to aggressively reshape the health care industry, ranging from new proposed rules to withdrawals of previous guidance, say attorneys at Fried Frank.

  • Calif. Climate Disclosure Bills Promise Challenges For Cos.

    Author Photo

    Two novel climate disclosure bills recently passed by the California Legislature will pose challenges for many businesses — especially private companies that are less familiar with climate-related reporting obligations — and will require investments of significant time and effort in processes, procedures and personnel, say John Rousakis and Chris Bowman at O'Melveny.

  • Maximizing Law Firm Profitability In Uncertain Times

    Author Photo

    As threats of an economic downturn loom, firms can boost profits by embracing the power of bottom-line management and creating an ecosystem where strategic financial oversight and robust timekeeping practices meet evolved client relations, says Shireen Hilal at Maior Strategic Consulting.

  • 7 Common Compliance Pitfalls For Multistate Pharmacies

    Author Photo

    In light of a California bill recently introduced to prevent medication errors at understaffed chain pharmacies — which could add yet another regulatory hurdle for certain establishments operating across the U.S. — pharmacies operating in multistate capacities must proactively mitigate operational risks, say attorneys at Troutman Pepper.

  • 5th Circ. Ruling Reminds Attys That CBP Can Search Devices

    Author Photo

    The Fifth Circuit’s recent Malik v. Department of Homeland Security decision adds to the chorus of federal courts holding that border agents don’t need a warrant to search travelers’ electronic devices, so attorneys should consider certain special precautions to secure privileged information when reentering the U.S., says Jennifer Freel at Jackson Walker.